Pharmaceutical giants today participate in a variety of healthcare-related projects, from vaccine development to clinical trials, they are also becoming strong players in the digital healthcare market, since their resources and influence can significantly shape or change the balance of power in this area.
The active development of domestic production sites stimulated the conclusion of memorandums of cooperation with multinational pharmaceutical companies. Kazakhstan's pharmaceutical market has become more attractive for localization of production of advanced drugs through technology transfer.
At the moment, the project is already being implemented within the framework of the Memorandum of Understanding signed in July between the pharmaceutical giant Novo Nordisk and the Ministry of Health of the Republic of Kazakhstan, and joint fruitful work is underway on health promotion and improving the treatment of socially significant diseases.
The agreement provides for active cooperation in supporting and developing domestic production of medicines, providing quality medical care through the implementation of projects on continuing medical education in the field of diabetes and obesity, building up scientific and research potential, providing earlier access to innovative therapies for patients with diabetes and obesity.
The signing of the Memorandum was preceded by a number of meetings and negotiations between the Single Distributor and Novo Nordisk on cooperation, as well as the realization of Kazakhstan's potential in the pharmaceutical industry.
Within the framework of cooperation, Novo Nordisk cooperates with the Ministry of Health of the Republic of Kazakhstan in the field of clinical research of diabetes mellitus treatment, provision of continuing education of healthcare professionals "Global Obesity clinics program" and programs for training Kazakhstani endocrinologists in modern methods of diabetes mellitus treatment.
Thus, 162 Kazakhstani specialists took part in the online course "Diabetes University", accredited by the Royal College of Doctors, UK (Royal College of Physicians, UK) with the provision of continuing medical education (CME) points. In general, since the beginning of the year, about 1,200 specialists of various specialties have been involved in educational events and conferences in the field of diabetes and obesity treatment.
Also, an important aspect in the framework of cooperation are projects in the field of clinical research in the territory of the Republic of Kazakhstan. In the future, it is planned to organize a study of a drug for the treatment of diabetes mellitus in the framework of real clinical practice, in accordance with international requirements for this type of research and in accordance with the legislation of the Republic of Kazakhstan.
Ensuring patients' access to innovative therapies in the field of diabetes and obesity will be implemented as part of the standard procedure for including drugs in the lists of outpatient and inpatient care in accordance with the legislation of the Republic of Kazakhstan, through the implementation of projects in the field of assessment of medical technology and impact on the budget.
It is worth noting that a single distributor has been purchasing 17 names of Novo Nordisk drugs since 2010, of which 9 names were purchased from the manufacturer's factory through a direct contract. In the procurement for 2022, 11 types of medicines were purchased under a direct contract.
On the Company Novo Nordisk
An international pharmaceutical company founded in 1923. The company's headquarters are located in the suburbs of Copenhagen, Denmark. The company has been a world leader in the development and production of medicines for the treatment of diabetes, obesity, hemophilia and others for almost 100 years. The company has been represented in the Republic of Kazakhstan since 1993.
From 1991 to the present day, the company has been increasing the availability of the most modern drugs, as well as conducting large-scale clinical studies, developing and implementing new effective strategies for disease prevention and promoting a healthy lifestyle.
It has 16 production sites in nine countries (Algeria, Brazil, China, Denmark, France, Japan, Russia, the UK and the USA) and 10 R&D centers in five countries (China, Denmark, India Research, the UK and the USA).
.png)
.jpeg)